Throughout the morning, Vickie Siculiano was doing activities with her 3-year-old son, Sean.

“I try to bring it into something that’s not just something to sit and play with, but sit and learn. And that’s just what I can do because I sit a lot,” Siculiano said.

She was diagnosed with multiple sclerosis in 2007. It’s a condition where an overactive immune system attacks the brain, spinal cord and optic nerves. Her mom, Debi Smith, said she was in denial when she first heard her daughter had MS.

“You start to think, what did I do? You know, is it me? Did I not take care when I was pregnant with her? Is it something genetic that I don’t know about,” said Smith.

She has something called primary progressive MS and only 10 percent of people have it. Hackensack University Medical Center’s Dr. Florian Thomas says for those patients there wasn’t a treatment available to slow down the disease progression. That was until last year, when the FDA approved the first one, Ocrevus.

“There are different approaches in calming down this overactive immune system. Ocrevus does this by eliminating a certain type of white blood cell, a lymphoside,” Thomas said.

Thomas says the attraction to this treatment is that it’s a twice-a-year infusion, which is compatible with an active lifestyle like Siculiano’s.

“She had the two half doses and then she just had the full treatment last time, and she can stand longer. I know that. When we take him [Sean] to ‘The Little Gym,’ she used to have to sit on the chair. She doesn’t do that anymore. She stands, with the crutches, but she stands there,” Smith said.